Literature DB >> 19383905

The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis.

Li Qin1, Zhaoliang Liu, Hongwu Chen, Jianming Xu.   

Abstract

In breast cancer, steroid receptor coactivator-1 (SRC-1) expression positively correlates with HER2 expression and poor prognosis. In mouse mammary tumor virus-polyoma middle T (PyMT) breast cancer mouse model, SRC-1 strongly promotes mammary tumor metastasis. However, the molecular targets and mechanisms that mediate the role of SRC-1 in metastasis are unknown. In this study, SRC-1 wild-type (WT) and knockout (KO) cell lines were developed from the mammary tumors of WT/PyMT and KO/PyMT mice. WT cells exhibited strong migration and invasion capabilities, reduced E-cadherin and beta-catenin epithelial markers, gained N-cadherin and vimentin mesenchymal markers, and formed undifferentiated invasive structures in three-dimensional culture. In contrast, KO cells showed slow migration and invasion, retained E-cadherin, had less N-cadherin and vimentin, and developed partially differentiated three-dimensional structures. Importantly, WT cells expressed Twist, a master regulator of metastasis, at significantly higher levels versus KO cells. SRC-1 knockdown in WT cells reduced Twist expression, whereas SRC-1 restoration in KO cells also rescued Twist expression. Furthermore, SRC-1 was found to coactivate Twist transcription through physical interaction with the transcription factor PEA3 at the proximal Twist promoter. Accordingly, Twist knockdown in WT cells increased E-cadherin and reduced cell invasion and metastasis, and Twist expression in KO cells decreased E-cadherin and increased cell invasion. SRC-1 knockdown in human breast cancer cells also decreased Twist, cell migration, and invasion. Therefore, SRC-1 promotes breast cancer invasiveness and metastasis by coactivating PEA3-mediated Twist expression. Intervention of SRC-1 function may provide new strategies to inhibit breast cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383905      PMCID: PMC2911143          DOI: 10.1158/0008-5472.CAN-08-4389

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations.

Authors:  S Y Na; S K Lee; S J Han; H S Choi; S Y Im; J W Lee
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

2.  Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity.

Authors:  Maggie C Louie; Alexey S Revenko; June X Zou; Jennifer Yao; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

Review 3.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

4.  Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.

Authors:  Eddie Myers; Arnold D K Hill; Gabrielle Kelly; Enda W McDermott; Niall J O'Higgins; Yvonne Buggy; Leonie S Young
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

Review 5.  New genes potentially involved in breast cancer metastasis.

Authors:  M Schwirzke; S Schiemann; A U Gnirke; U H Weidle
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

6.  Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene.

Authors:  J Xu; Y Qiu; F J DeMayo; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Science       Date:  1998-03-20       Impact factor: 47.728

7.  The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12.

Authors:  Hiromitsu Kishimoto; Zhuo Wang; Poornima Bhat-Nakshatri; David Chang; Robert Clarke; Harikrishna Nakshatri
Journal:  Carcinogenesis       Date:  2005-05-25       Impact factor: 4.944

8.  Loss-of-function deletion of the steroid receptor coactivator-1 gene in mice reduces estrogen effect on the vascular injury response.

Authors:  Yuhui Yuan; Jianming Xu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-04-19       Impact factor: 8.311

9.  An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response.

Authors:  Chundong Yu; Brian York; Shu Wang; Qin Feng; Jianming Xu; Bert W O'Malley
Journal:  Mol Cell       Date:  2007-03-09       Impact factor: 17.970

10.  A positive role for PEA3 in HER2-mediated breast tumour progression.

Authors:  E Myers; A D K Hill; G Kelly; E W McDermott; N J O'Higgins; L S Young
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

View more
  83 in total

1.  Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer.

Authors:  Damian McCartan; Jarlath C Bolger; Aílis Fagan; Christopher Byrne; Yuan Hao; Li Qin; Marie McIlroy; Jianming Xu; Arnold D Hill; Peadar Ó Gaora; Leonie S Young
Journal:  Cancer Res       Date:  2011-11-09       Impact factor: 12.701

2.  Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.

Authors:  Larbi Amazit; Audrey Roseau; Junaid A Khan; Anne Chauchereau; Rakesh K Tyagi; Hugues Loosfelt; Philippe Leclerc; Marc Lombès; Anne Guiochon-Mantel
Journal:  Mol Endocrinol       Date:  2011-01-27

3.  ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

Authors:  Ekaterina V Kalashnikova; Alexey S Revenko; Abigael T Gemo; Nicolas P Andrews; Clifford G Tepper; June X Zou; Robert D Cardiff; Alexander D Borowsky; Hong-Wu Chen
Journal:  Cancer Res       Date:  2010-09-23       Impact factor: 12.701

4.  Targeting steroid receptor coactivator 1 with antisense oligonucleotides increases insulin-stimulated skeletal muscle glucose uptake in chow-fed and high-fat-fed male rats.

Authors:  Jennifer L Cantley; Daniel F Vatner; Thomas Galbo; Anila Madiraju; Max Petersen; Rachel J Perry; Naoki Kumashiro; Fitsum Guebre-Egziabher; Arijeet K Gattu; Mitchel R Stacy; Donald P Dione; Albert J Sinusas; Louis Ragolia; Christopher E Hall; Vara Prasad Manchem; Sanjay Bhanot; Jonathan S Bogan; Varman T Samuel
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

Review 5.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

6.  α-Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling.

Authors:  Ying Sun; Yanyan Ding; Chen Guo; Chengmin Liu; Ping Ma; Shuang Ma; Zhe Wang; Jie Liu; Tao Qian; Luyao Ma; Yi Deng; Chuanyue Wu
Journal:  Oncogene       Date:  2019-02-25       Impact factor: 9.867

7.  Twist expression associated with the epithelial-mesenchymal transition in gastric cancer.

Authors:  Ai-ning Liu; Zhi-Hua Zhu; Shu-jian Chang; Xiao-sheng Hang
Journal:  Mol Cell Biochem       Date:  2012-05-13       Impact factor: 3.396

8.  Steroid receptor coactivator 1 is an integrator of glucose and NAD+/NADH homeostasis.

Authors:  Massoud Motamed; Kimal I Rajapakshe; Sean M Hartig; Cristian Coarfa; Robb E Moses; David M Lonard; Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2014-01-17

9.  HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.

Authors:  Jie Chen; Jun Xia; Yong-lin Yu; Si-qun Wang; Yi-bing Wei; Fei-yan Chen; Gang-yong Huang; Jing-sheng Shi
Journal:  Tumour Biol       Date:  2013-10-05

10.  ETS1 regulates Twist1 transcription in a KrasG12D/Lkb1-/- metastatic lung tumor model of non-small cell lung cancer.

Authors:  Guetchyn Millien; Yuxia Cao; Carl J O'Hara; Jean-Bosco Tagne; Anne Hinds; Mary C Williams; Maria I Ramirez; Hasmeena Kathuria
Journal:  Clin Exp Metastasis       Date:  2018-06-16       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.